Repeat entrepreneur is a term you might hear often in the context of life sciences company creation and investment, so we wanted to take a moment to unpack it and offer lessons for those on either side of the table.
As interest in the cell and gene market continues to heat up, the sector’s manufacturing and finance challenges have become top priorities.
A summary of some key sections of version 10 of Deloitte’s Life Sciences Accounting And Financial Reporting Update—Including Interpretive Guidance.
Sam Cobb, managing director and CEO of Australian biotech AdAlta, talks about how the company has struggled to procure funding over the years and the strategies they employed to finally get listed on the Australian Securities Exchange.
Growing a life sciences company will have continuous demands for funding. Wherever that money comes from, undertaking a commitment to PCAOB (Public Company Accounting Oversight Board) compliance will be valued by potential investors.
“Normally a company raises money, does their science, and hopes to get a deal. We were the inverse of that,” explains Joseph Payne, president and CEO of Arcturus Therapeutics.
The value of China’s biotechs fell some 30 percent since the trade war began, and VC funding, while strong, slipped before that. Interest in China, however, remains strong.
Biopharma and medtech companies are expecting mostly positive results from the new Tax Cuts and Jobs Act (TCJA), according to research by The Deloitte Center for Health Solutions and Forbes Insights.
There’s no doubt that partnerships and M&As are key growth drivers in the biopharma industry. But for collaborative relationships to occur, understanding the value of a company’s underlying assets is critical.
Foghorn Therapeutics is managing to sidestep some of the growing pains common to early companies, thanks to its genesis as a VC-founded company.